B+
Bull case
30%
Probability
Target price
$30.00
+20.0% vs current
PGNY
ProgynyANasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$25.00
+0.0% vs current
B-
Bear case
25%
Probability
Target price
$18.00
-28.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+46.0
Score
AI commentary
Headline tone improved materially on May 7-8, 2026 because the company paired a solid Q1 report with a modest upward revision to the full-year revenue floor, and the stock rallied about 22.4% on May 8 versus the May 7 close. That said, this is still an early T+1 follow-up run: immediate analyst target and estimate revisions were not available in the packet, so the reaction looks more like relief plus guidance stabilization than a fully digested re-rating. Social coverage was not provided, so monitoring should stay anchored to filings and subsequent revision data rather than narrative momentum.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-08eventQ1 print de-risked the February reset and lifted the 2026 revenue floorHigh impact
Progyny reported record Q1 2026 revenue of $328.5 million, gross margin of 25.3%, net income of $24.2 million, and said there was no contribution from the previously disclosed non-renewed large client in the quarter; it also raised the low end of full-year 2026 revenue guidance to $1.365 billion from $1.355 billion while keeping the high end at $1.405 billion [#8-K-2026-05-07].
2026-05-31catalystBoard decision on a new repurchase authorization is a near-term support watchpointHigh impact
The company completed its November 2025 $200 million repurchase authorization by March 31, 2026 after buying 8.8 million shares cumulatively, and management said the board was evaluating options for a new program with an announcement anticipated around the end of May; that can matter for support after the post-earnings rebound [#8-K-2026-05-07][#10-Q-2026-05-08].
2026-12-31catalyst2026 client launches and selling-season traction need to convert into cleaner reported growthHigh impact
Management said most recent selling-season wins went live in Q1, a handful of additional clients are expected to launch in Q2, and the company continues to expect more than 600 clients and about 7.2 million covered lives once all 2026 launches are live; if that demand converts without another utilization or client-mix disappointment, the growth narrative can improve through 2026 [#8-K-2026-05-07][#10-Q-2026-05-08].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology